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Introduction
The insulin-like growth factor (IGF) system has been shown to play a role in the progression of breast cancer via activation of the IGF-I receptor.
IGF-I also binds with high affinity to a family of proteins called the IGF binding proteins (IGFBPs), which serve as natural IGF-l inhibitors through sequestration of IGF-l from its receptor.
Currently no therapeutic IGF antagonists exist. The purpose of this project is the development of novel therapeutic IGF antagonists based on the structure of the IGFBPs. A photoaffinity labeling approach is being used to identify the IGF binding domains on the IGFBPs. This information will be used in the rational design of therapeutic IGF-l antagonists for use in the treatment of breast cancer.
Body
Specific Aim 1 as outlined in the Statement of Work involves expression of IGFBP-3 and IGFBP-5 in bacterial and mammalian expression systems.
The cDNA for IGFBP-5 has been successfully cloned into an inducible bacterial expression system.
The protein is produced by the bacteria, which are then lysed to collect the cell contents that contain the IGFBP.
The bacteria makes the IGFBP in an unfolded state that must be treated with reducing agents (such as urea) and then carefully refolded to obtain the native, disulfide-bond containing conformation of the protein.
The current yield from an average preparation from bacteria (500 ml culture) is low, however, in microgram quantities instead of the expected milligram amounts even in the presence of the inducing agent isopropyl P-D-l-thiogalactopyranoside (IPTG). The purification procedure is currently being optimized to include clones of bacteria that have demonstrated higher expression of the binding protein.
The cDNA for IGFBP-3 has been successfully transfected into Chinese hamster ovary (CHO) cells for mammalian expression, which secrete the protein in its native folded and glycosylated form.
Clones that express IGFBP-3 are currently being isolated and analyzed to determine protein yield. Several clones were previously isolated that expressed IGFBP-3 but these cells were lost due to contamination problems in the tissue culture facility. New clones are currently being analyzed and will be used to collect significant amounts of This expression system involves using methotrexate to induce amplification of the IGFBP-3 DNA incorporated into the mammalian chromosome.
Increasing concentrations of methotrexate in the feeding media are being used to amplify the amount of protein being produced by the CHO cells.
This has been a slow process because it takes time for the cells to adapt to the presence of methotrexate in their media, which initially kills a large percentage of the cells. A bacterial expression system has not been developed for IGFBP-3 as yet, and IGFBP-5 cDNA has not yet been transfected into CHO cells for mammalian expression.
In the meantime, we have been purchasing recombinant IGFBP-3 in order to perform our photoaffinity labeling experiments.
This form of IGFBP-3 has been prepared in bacteria and is therefore non-glycosylated.
Bacterially expressed IGFBP-5 is not currently commercially available; therefore the experiments outlined using IGFBP-5 have not been performed.
Photoaffinity labeling experiments have been carried out using IGF-l derivatized at the Gly-i residue using .
This photoprobe, referred to as abGlyl-IGFl, has been crosslinked to IGFBP-3 as outlined in Specific Aim 1. Mass spectrometric analysis of the reduced and alkylated and trypsin digested photolabeled complex reveal photoincorporation of the IGF photoprobe into the midregion of the IGFBP-3 protein.
This result is unexpected based on our hypothesis, which predicted that the carboxy terminus of IGFBP-3 would be identified as involved in IGF binding.
The experiments with IGFBP-3 had been performed using IGF-1 derivatized using the crosslinking reagent sulfosuccinimidyl-2-[-6-(biotinamido)-2-(p-azidobenzamido)-hexanoamido]ethyl-i,3'-dithiopropionate (SulfoSBED), however these experiments have so far failed to yield significant mass spectrometric data.
This could be due to an issue with the mass spectrometry equipment since polyacrylamide gel electrophoresis (SDS-PAGE) data indicated a significant amount of crosslinking efficiency using this IGF photoprobe (bedGlyl-IGFl) .
These experiments are being repeated to confirm these findings, including carrying out the mass spectrometric analysis.
Specific Aim 2 of the Statement of Work involved identifying a potential site of interaction between the IGFBPs and the IGF-I receptor binding domain on IGF-l using crosslinking reagents attached to the Lys-27 residue of IGF-I, a residue that is located near the IGF-l receptor binding domain.
This photoprobe is known as abLys27-IGFl. Preliminary photoaffinity labeling experiments show that this photoprobe does crosslink to IGFBP-3 as seen by SDS-PAGE analysis, however the site of contact has not yet been identified by mass spectrometry.
These experiments will be repeated as well, in order to identify the site of abLys27-IGFl crosslinking to IGFBP-3. These studies will help determine if the IGFBPs interact with the receptor-binding domain on IGF-l, thus suggesting a mechanism by which the IGFBPs inhibit IGF-1 access to its receptor.
Key Research Accomplishments
0 IGFBP-5 has been expressed in an inducible bacterial expression system (E. coli) and the purification procedure is currently being optimized.
* IGFBP-3 has been expressed in a mammalian expression system (CHO cells) and the system is currently being optimized.
0 Photoaffinity labeling of IGFBP-3 using abGlyl-IGFl identified the midregion of IGFBP-3 as being involved in IGF binding.
0 Photoaffinity labeling of IGFBP-3 using abLys27-IGFl indicated that crosslinking occurred, however the site of contact has not yet been identified by mass spectrometric analysis.
Reportable Outcomes
1.
At the time of submission of this proposal, we had been preparing a manuscript for publication in the Journal of Biological Chemistry.
Since that time the manuscript has been reviewed and accepted (Ref.
1, Appendix 1).
The data included in this paper was supported by NIH CA-78887 and Grant-in-aid S9868S from the American Heart Association to SA Rosenzweig and was used as preliminary data in preparation of this proposal.
A copy of this journal article is included in the appendix section of this report.
2. The work described in this report has been presented at the 8 4 th annual meeting of the Endocrine Society, of which I am a fellow/student member. The data was presented in poster format on June 20, 2002 in San Francisco, CA.
3. I have completed all required courses for our department as well as successfully passed a written qualifying test that examines all aspects of my course training to date. I am currently preparing for an oral examination in which I will present specific aims of my project and defend the rationale to the departmental faculty.
Upon completion of these exams, I will be accepted as an official Ph.D candidate in the Dept. of Pharmacology at the Medical University of South Carolina.
Conclusions
In conclusion, several points of Specific Aim 1 of the proposed Statement of Work have been completed. IGFBP-3 has been expressed in a mammalian system, and IGFBP-5 has been expressed in a bacterial system, and both systems are currently being adjusted to promote optimal protein yield. Current photoaffinity labeling experiments with IGFBP-3 have identified the midregion of the protein as being involved in IGF-1 binding. This is an important finding because a number of studies in the literature have implicated either the carboxy or amino terminus as containing the binding site for IGF-I.
While this data does not negate the importance of either of these regions of the binding proteins, it suggests that the midregion of the IGFBPs may also play an important role in IGF-I binding.
This finding is different from what we found with IGFBP-2 (Ref. 1, Appendix 1), so we can conclude that the interactions of the IGFBPs are unique to each protein in the sense that each binding protein interacts with IGF-l using a different mechanism.
In addition, the first point of Specific Aim 2 has begun, however the data has not been completely analyzed as of yet.
The information gained from these studies will aid in the development of novel IGF antagonists based on the structure and function of the IGFBPs.
Elevated insulin-like growth factor (IGF)-1 levels are roles in a number of cellular processes, including growth, proprognostic for the development of prostate and breast liferation, differentiation, survival, transformation, and metascancers and exacerbate the complications of diabetes. In tasis (1, 2). Enhanced activity of the IGFs has been implicated each case, perturbation of the balance between IGF-112, in diabetic complications and cancer. These effects are medithe IGF-1 receptor, and the IGF-binding proteins (IGF-ated by the IGF-1 receptor (IGF-1R), a member of the receptor BPs) leads to elevated IGF-1 sensitivity. Blockade of IGF tyrosine kinase family of cell-surface receptors. The IGF-2 reaction in these diseases would be clinically significant. ceptor, which lacks signaling activity, plays a role in clearing Unfortunately, effective IGF antagonists are currently IGF-2 from the cell surface (3, 4) . The IGFs are regulated at unavailable. The IGFBPs exhibit high affinity and spec-the extracellular level by a family of six IGF-binding proteins ificity for the IGFs and serve as natural IGF antagonists, (IGFBPs), designated IGFBP-1-6 (5-7). These six proteins exlimiting their mitogenic/anti-apoptotic effects. As an hibit higher affinities for the IGFs than the IGF-1R, while initial step in designing IGFBP-based agents that antag-having negligible affinity for insulin. Accordingly, increased serum'IGF-i IGF-1 (bedG'IGF-1), selective for the IGFBPs were syn-levels have been shown to be prognostic for the development of thesized by derivatization of the a-amino group of Gly 1 , prostate and breast cancers (9, 10). Alterations in IGFBP exknown to be part of the IGFBP-binding domain. Mass pression may also contribute to disease states. For example, spectrometric analysis of the reduced, alkylated, and IGFBP-3 is a target of the p53 tumor suppressor, and a comtrypsin-digested abG'IGF-lrecombinant human mon p53 mutation results in decreased IGFBP-3 secretion (11, IGFBP-2 (rhIGFBP-2) complex indicated photoincorpo-12), which is likely to cause an increased proliferative response ration near the carboxyl terminus of rhIGFBP-2, be-to IGF-1. Also, reduced IGFBP-2 expression resulting from the tween residues 266 and 287. Mass spectrometric analysis hyperglycemia of diabetes was recently shown to enhance the of avidin-purified tryptic peptides of the bedGIIGF-sensitivity of renal mesangial cells to the growth and secretory 1.rhIGFBP-2 complex revealed photoincorporation effects of IGF-1, pushing the cells toward a glomerulosclerotic within residues 212-227. Taken together, these data inphenotype (13). Because IGF-1 can suppress apoptosis, cells dicate that the IGFBP-binding domain on IGF-1 con-lacking IGF-1 receptors, cells with compromised IGF-1R sigtacts the distal third of IGFBP-2, providing evidence naling pathways, or cells treated with the IGFBPs may selecthat the IGF-1-binding domain is located within the C tively die by apoptosis (8). Taken together, these findings sugterminus of IGFBP-2.
gest that the IGFBPs serve a role as natural IGF antagonists. IGF-1 and IGF-2 are homologous protein hormones of 70 and r(IGF)-1 and IGF-2 play central 67 amino acids in length, respectively (14) . Based on studies of, chemically modified and mutated IGF-1, a number of residues have been identified as being part of the IGF-1R contact site, in * This work was supported in part by Grant CA-78887 from the particular the aromatic residues at positions 23-25 (15). Cooke National Institutes of Health and Grant-in-aid S9868S from the Amer-et al. (16) used NMR and restrained molecular dynamics to ican Heart Association, South Carolina Affiliate (to S. A. R.). A portion of this work was presented at the 82nd Annual Meeting of the Endo-elicit the solution structure of IGF-1; this model clearly illuscrine Society, June 21-24, 2000, Toronto, Ontario, Canada. The costs of trates an IGFBP-interacting domain on the surface of IGF-1 publication of this article were defrayed in part by the payment of page and its lack of overlap with the receptor-docking site (see Fig.  charges . This article must therefore be hereby marked "advertisement" 1). Specifically, this site consists of the N-terminal tripeptide in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
t To whom correspondence should be addressed: Dept. of Cell and Gly-Pro-Glu (17) and residues 49-51 (18) . These two regions Molecular Pharmacology and Experimental Therapeutics, Medical Uni-come together to form an independent binding domain (see tact site on IGF-1 for binding protein specificity (17). In addi-EXPERIMENTAL PROCEDURES tion, mutations of Glu3 or residues 49-51 result in a ligand Materials-Recombinant human IGF-1 was provided by Genentech, with severely reduced binding activity (19). In good agreement Inc. (South San Francisco, CA). HSAB was synthesized from p-aminowith these findings, insulin lacks these residues common in the benzoic acid, sodium azide (Sigma),and dicyclohexylcarbodiimide IGFBP-binding region and thus does not bind to the IGFBPs (Pierce) and purified according to the method of Galardy et al. (26) .
HPLC columns were from Vydac Instruments (Hesperia, CA). SBED, with high affinity.
UltraLinkTM monomeric avidin-agarose, NeutrAvidin TM -peroxidase, The IGFBPs are globular proteins containing 18 spatially and tris(2-carboxyethylyl)phosphine hydrochloride were obtained from conserved cysteine residues participating in the formation of Pierce. Methotrexate was from Immunex Corp. (Seattle, WA), and fetal nine disulfide bonds. They range in size from 200 to 300 amino bovine serum was from Summit Biotechnology (Fort Collins, CO). cDNA acids and, based on their high degree of homology, can be encoding human IGFBP-2 (27) was obtained from Dr. Jorg Landwehr divided into three distinct domains, each constituting about (Hoffmann-La Roche, Basel, Switzerland). All other materials were of reagent grade or higher.
one-third of the protein (20) . The N-and C-terminal regions, Synthesis and Purification of abG'IGF-1 and bedG 1 IGF-1-All deridesignated domains 1 and 3, respectively, share the highest vatizations and handling of photoprobes were carried out under subhomology (20, 21), whereas the intervening region (domain 2) is dued lighting or under a red safety light. abG'IGF-I was synthesized by highly variable (<30% homology) (6) . Domains 1 and 3 contain reaction of recombinant human IGF-1 (1 mg, 130 nmol) with a 10-fold 12 and 6 spatially conserved cysteine residues, respectively, molar excess of HSAB (0.34 mg, 1.3 umol) for 1 h at 23 *C. Unreacted ester was quenched by the addition of 30 1 .1 of ethanolamine for 30 min, except in the case of IGFBP-6, which is missing 2 cysteine and the entire reaction mixture was lyophilized. The lyophilized reacresidues in domain 1 (5); IGFBP-4 has 2 additional cysteine tion mixture was dissolved in 0.5 M acetic acid and 10 pl of trifluororesidues in domain 2. Because of the high homology of these acetic acid and injected onto a C 1 , column equilibrated in 0.1% trifluproteins in domains 1 and 3 (-70%) (6), the IGF-binding do-oroacetic acid and 24% acetonitrile at a flow rate of 1 ml/min. After 20 main has been proposed to reside within one of these regions. min, a linear gradient of 24-60% acetonitrile was developed over 60 Support for this notion is based on studies in which N-or min to elute IGF-1 and the reaction products. Peak 4 was collected, dried in vacuo in a SpeedVac concentrator (Savant Instruments, Inc., C-terminal IGFBP fragments were found to retain high affinity Farmingdale, NY), reinjected onto the C,, column equilibrated in 50 mM binding activity for IGF-1 and/or IGF-2 (19). IGFBP-related triethanolamine phosphate (pH 3.0) containing 27.5% acetonitrile, and protein-1 and -2, also known as IGFBP-7/Mac25 and IGFBP-8/ eluted with a gradient of 27.5-38% acetonitrile over 60 min. The major connective tissue growth factor, respectively, have homologies peak was collected, dried, and further analyzed. Synthesis and purifiwithin their N termini to IGFBP-1-6 (23). These proteins have cation of bedG'IGF-1 was carried out essentially as described for lower affinities for the IGFs compared with the IGFBPs and abG'IGF-1 using a 1:1 ratio of SBED to protein.
Pepsin Digestion of abG'IGF-1 and bedG'IGF-1-IGF-1 and the pho-
have been reported to interact with insulin (24). The precise toprobes were digested with pepsin at an enzyme/substrate ratio of 1:20 mechanism by which the IGFBPs inhibit IGF-1 and IGF-2 in 0.01 M HC1 for 5 h at 23 °C (28). Digests were then injected onto a C,, action is presently unknown. It is thought to involve high column equilibrated in 0.1% trifluoroacetic acid, and the fragments affinity binding of the IGFs by the IGFBPs, thereby limiting were eluted using a linear gradient of 0-60% acetonitrile over 90 min. their access to the IGF-1R. A complete understanding of this For each photoprobe, the HPLC fractions containing fragments with inhibitory action will come with the solution of the three-potentially modified residues (AE, CG, and D fragments) (see Fig. 3 ) (28) were analyzed by matrix-assisted laser desorption/ionization timedimensional structure of the IGFBPs. As of yet, the IGF-bind-of-flight mass spectrometry (MALDI-TOF-MS). ing domain on the IGFBPs has not been defined.
MALDI-TOF-MS-Dried HPLC fractions were dissolved in 0.1% triTo date, extensive use of molecular techniques has been fluoroacetic acid containing 70% acetonitrile. 0.5-td aliquots of each applied to assess the binding domain on the IGFBPs. However, fraction were mixed with 1 1 1 of 50 mm a-cyano-4-hydroxycinnamic acid only sparse structural information has been obtained. Cur-(Sigma) in 0.1% trifluoroacetic acid and 70% acetonitrile. The mixture rently, a debate exists as to which domain(s) of the IGFBPs are was spotted onto a gold-coated, stainless steel sample plate and airdried. The samples were analyzed using a PerSeptive Biosystems Voymost crucial for IGF binding. This is further confounded by the ager-DE MALDI-TOF mass spectrometer equipped with a 337-nm nipaucity of precise structural information about the IGFBPs as trogen laser. A delayed extraction source was operated in linear mode recently reviewed by Baxter (25) . To more precisely identify the (1.2-m ion flight path, 20-kV accelerating voltage), yielding an instrupoints of contact between IGF-1 and IGFBP-2, we chose to mental resolution of -700 (full width at half-maximum) at m /z 1297.5. pursue a photoaffinity labeling approach, which has been used One mass spectrum was based on 256 averaged mass scans. External mass calibration was performed using angiotensin 1 (1297.5 Da) and to identify sites of interaction between a number of interacting bovine insulin (5734.54 Da) as standards. Mass accuracy was ±0.1%. proteins. On this basis, we derivatized the a-amino group of the Purification of rhIGFBP-2-rhIGFBP-2 was purified from DHFR-N-terminal glycine of IGF-1 with two different photoaffinity Chinese hamster ovary cells (29) stably transfected with 30 jg of reagents, N-hydroxysuccinimidyl 4-azidobenzoate (HSAB) and pCMV-hIGFBP-2 and 2 gg of pMT2 containing murine dihydrofolate sulfosuccinimidyl [2-6-(biotinamido)-2-(p-azidobenzamido)-reductase (30) using calcium phosphate. Cells were grown to confluence hexanoamido]ethyl-1,3'-dithiopropionate (SBED), to generate in roller bottles and subjected to a weekly cycle of 3 days growth in serum-containing medium, followed by 4 days in serum-free medium. IGF-1 photoprobes capable of selectively labeling the IGF-bind-Pooled conditioned medium (400-600 ml) was acidified to pH 3-4 with ing domain on IGFBP-2. The advantage of this approach is that glacial acetic acid and dialyzed against 10 mm acetic acid in Spectrapor the photoreactive group is inserted within the region shown to 4 membranes (12,000-14,000 M, cutoff; Spectrum, Laguna Hills, CA) to be essential for high affinity binding of IGF-1 to the IGFBPs. remove salt and IGFs. After lyophilization, IGFBP-2 was purified by Since IGF-2, which has a 3-residue N-terminal extension, ex-sequential IGF-1-agarose affinity chromatography and reversed-phase hibits a higher affinity for IGFBP-2 than IGF-1, reduced bind-HPLC on a C 4 column equilibrated in 0.1% trifluoroacetic acid.
IGFBP-2 eluted between 30 and 40% acetonitrile. ing affinity of IGF-1 for IGFBP-2 resulting from N-terminal IGF-1-Agarose Affinity Chromatography-2 ml of Affi-Gel 10-actisubstitutions was not anticipated. In this study, we describe vated immunoaffinity support (Bio-Rad) were washed four times with 3 the synthesis and characterization of NcGIY'-(4-azidobenzoyl)-volumes of cold water, followed by the addition of 2 mg of IGF-1 in 100 IGF-1 (abG'IGF-1) and N•Glyl-([2-6-(biotinamido)-2-mM HEPES (pH 7.4). The mixture was agitated overnight at 4 °C, (p-azidobenzamido)hexanoamidolethyl-1, 3'-dithiopropionoyl)-followed by two washes with 100 mM HEPES (pH 8.0). Unreacted sites IGF-1 (bedG'IGF-1) and their successful application to pho-were then quenched with 2 ml of 1 M Tris-HC1 (pH 7.9) for 1 h at ambient temperature. The column was then washed with three cycles of toaffinity label rhIGFBP-2. Based on these direct photoaffinity alternating low pH/high pH salt washes (0.5 M NaCl and 0.1 M sodium labeling analyses, our results indicate that the C terminus of acetate (pH 4.0) and 0.5 M NaC1 and 0.1 M Tris (pH 8.0), respectively). IGFBP-2 contains the IGF-binding domain.
Finally, the column was washed and stored in 10 ml of 150 mm NaC1 and 50 mM HEPES (pH 7.4) with 0.05% sodium azide. Dialyzed and lyophilized conditioned medium was dissolved in 40-45 ml of 50 mM HEPES (pH 7.4) containing 150 mM NaCl (Buffer A).
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min. 2 ml of IGF-1-agarose in Buffer A were then added, and the slurry was incubated overnight at 4 *C with gentle agitation. The column was Phe 49 subsequently washed with 100 ml of Buffer A, followed by 50 ml of 10%
Pro 2
Buffer A. Proteins bound to the column were then eluted with 15 ml of 0.5 M acetic acid, and the column was washed with 20 ml of Buffer A plus 1 ml of 1 M HEPES (pH 7.4), followed by 40 ml of Buffer A. The eluate was dried in vacuo using a SpeedVac concentrator. The dried (6) . Note that the Gly 1 a-NH 2 group is the site abG 1 IGF-1, or bedG'IGF-1 ranging from 30 fm to 100 nM in binding chosen for derivatization with aryl azide-based photoaffinity reagents. assay buffer (100 mm HEPES (pH 7.4), 44 mm NaHCO., 0.01% bovine Right, the IGF-IR-binding domain on IGF-1. The image was obtained serum albumin, 0.01% Triton X-100, and 0.02% NaN 2 ), followed by the by RasMol Version 2.6 using coordinates (6) from the Protein Data addition of 10 nCi of ' 2 I-IGF-1 (Amersham Pharmacia Biotech). After Bank, Research Collaboratory for Structural Bioinformatics, Rutgers a 4-h incubation at room temperature, 250 1l of 0.5% bovine y-globulin University (New Brunswick, NJ). were added, followed by 500 1A of 25% polyethylene glycol (average M, of 8000; Sigma). The samples were incubated for 10 min at room 10 min at 23 0C, followed by blocking for 1 h with 5% nonfat dry milk temperature and centrifuged for 3 min at 15,000 X g. The pellets were and reprobed. washed with 1 ml of 6.25% polyethylene glycol, and bound radioactivity was quantified in a Compugamma spectrometer (LKB-Wallac, Turku, RESULTS Finland). Counts bound in the presence of 1 /•M or 100 nM IGF-1 (nonspecific binding) were subtracted to obtain specific binding. HSAB and SBED. Fig. 2 shows the structures of these reagents Photoaffinity Labeling-Equimolar quantities of abG'IGF-1 or and highlights the relative lengths of the spacer arms from the bedG 1 IGF-1 and rhIGFBP-2 were allowed to attain equilibrium binding site of covalent linkage to IGF-1 to the photoreactive azide by co-incubation for 4 h at 23 *C in 100 mM HEPES (pH 7.4) containing group. In addition to a significantly longer spacer arm, SBED 44 mm NaHCO 3 and 0.01% Triton X-100. The sample was then placed also contains a reduction-sensitive disulfide linkage and a bioin ice water and irradiated for 2 h with a prewarmed Fotodyne handheld, single-wavelength UV lamp (2 × 4-watt 300-nm bulbs) at a dis-tin moiety. As a result, although we anticipated that use of tance of 2 cm. The mixture was dried in vacuo, and the proteins were HSAB as a photocross-linking agent would yield a reductionreduced and alkylated using tris(2-carboxyethylyl)phosphine (32) and stable covalent IGF-1.IGFBP-2 complex, use of SBED was ex-4-vinylpyridine (33). abG'IGF-1-and bedG'IGF-1-photolabeled IGFpected to produce a reduction-sensitive IGF-1-IGFBP-2 com-BP-2 proteins were separated from unreacted IGFBP-2 by reversedplex that, after reduction, would result in biotinylation of phase HPLC and trypsinized as described below.
Trypsinization of IGF-1, IGFBP-2, and Photoaffinity-labeled Complexes-Trypsinization of reduced and alkylated proteins was perAs shown in Fig. 2 , reaction of HSAB and SBED with IGF-1 formed according to Honegger and Humbel (34) . Proteins (20 MM) were as described under "Experimental Procedures" resulted in prodissolved in 100 mm N-ethylmorpholine acetate (pH 8.5) to which was duction of three major products (peaks 2-4) in addition to added sufficient trypsin (1 /g//l) to achieve a 1:50 enzyme/substrate unreacted IGF-1 (peak 1). Analysis of the HSAB reaction prodratio. Mixtures were then incubated for 2 h at 37 0C, followed by a ucts by acidic polyacrylamide gel electrophoresis in 8 M urea second addition of trypsin. After 2 additional h at 37 'C, the reaction and by MALDI-TOF-MS revealed that these three peaks were was stopped by the addition of an equal volume of 0.1% trifluoroacetic acid. The mixture was dried in vacuo or applied directly to a C., monoderivatized forms of IGF-1 (data not shown). 
) (36). Peaks 3 and 4 had been
Tryptic peptides generated from the bedG'IGF-1IGFBP-2 complex tentatively identified as abKeSIGF-1 and abG 1 IGF-1, respecwere applied to an UltraLinkTM monomeric avidin column. Flow-tively, based on amino acid sequencing analysis (36). No through fractions were collected and pooled. The column was eluted abKesIGF-1 was detected. The three product peaks were farwith low pH buffer, and the eluate fractions were pooled. The flowthrough and eluate fractions were dried and further analyzed by re-ther purified by chromatography on a Cis column equilibrated versed-phase HPLC on a Cl, column equilibrated in 0.1% trifluoroacetic in triethanolamine phosphate and acetonitrile. Structural asacid and eluted with a linear gradient of acetonitrile. Eluted peaks were signments were confirmed using pepsin digestion as described analyzed by MALDI-TOF-MS.
below. After derivatization with SBED, peaks 2-4 were shown Immunoblots-Samples were dissolved in SDS sample buffer with or to similarly represent bedK 2 7 IGF-l,, bedK1 5 IGF-1, and without dithiothreitol and resolved on a 10 or 12.5% SDS-polyacrylbedG'IGF-1 (Fig. 2B ). amide gel according to the procedure of Laemmli (35) using a Hoefer Scientific Instruments apparatus. The proteins were transferred to Characterization of abGIGF-1 and bedGIGF-1-To verify nitrocellulose and immunoblotted using a commercial antiserum that the "ab" and 'ted" moieties were covalently bound to the against intact bovine IGFBP-2 (Upstate Biotechnology, Inc., Lake a-amino group of Gly 1 for each photoprobe, it was necessary to Placid, NY). Blots were developed with horseradish peroxidase-labeled isolate Gly' from the 3 Lys residues. Since reduction and alkysecondary antibody (Chemicon International, Inc., Temecula, CA) and lation might disrupt the azide moiety, we utilized pepsin digesan enhanced chemiluminescence kit (Amersham Pharmacia Biotech).
tion of nonreduced abGIGF-1 and bedG'IGF-1. As reported by For sequential anti-IGF-1/anti-IGFBP-2 antibody analysis of the same blot, the membrane was stripped for 20 min at 60 oC in 1 m Tris (pH 6.7)
Forsberg et al. (28) and shown in Fig. 3 , pepsin releases a containing 10% SDS and 0.1 M P-mercaptoethanol. The stripped memdisulfide-linked AE fragment containing Gly' and no Lys resbrane was washed twice with Tris-buffered saline containing Tween for idues. Pepsin digestion of abG'IGF-1 and bedG'IGF-1 was IGF-1 at its N-terminal glycine residue, purified probes were digested Photoaffinity Labeling ofIGFBP-2-Photoaffinity labeling of with pepsin. The primary sequence of IGF-1 is shown, with arrowheads indicating the primary sites of pepsin cleavage (28). Letters A-G indi-IGFBP-2 with abG'IGF-1 and bedG'IGF-1 was carried out as cate the principal peptides generated. The disulfide-linked AE fragment described under "Experimental Procedures." In a small-scale (shaded) contains the N-terminal glycyl residue and none of the lysyl photolabeling study with abG 1 IGF-1, an aliquot of the reaction residues.
mixture was subjected to immunoblot analysis with anticarried out in the dark to avoid photoactivation of the probe, IGFBP-2 and anti-IGF-1 antisera under reducing conditions and recombinant human IGF-1 was also digested in parallel to (Fig. 7A) . In addition to rhIGFBP-2 migrating at -32 kDa and serve as a control for subsequent HPLC and mass spectromet-detected by anti-IGFBP-2 antiserum, a second protein species ric analyses. migrating at -40 kDa was detected. This band reacted with For each photoprobe, HPLC purification of the pepsin diges-both anti-IGF-1 and anti-IGFBP-2 antibodies, indicating that tion products revealed that the retention times for the derivat-the photoaffinity labeling reaction had successfully generated ized AE fragments were significantly increased compared with abG'IGF-1.IGFBP-2 complexes. These data confirm that phothe underivatized AE fragment (data not shown). This was tolabeling of IGFBP-2 with abG'IGF-1 results in a stable copredicted based on the added hydrophobicity of the additional valent IGF-1IGFBP-2 complex that is not disrupted by functional groups. Fig. 4A shows the MALDI-TOF-MS of reduction. abG 1 AE. This fragment had the correct mass (predicted aver-A similar analysis was carried out for bedG'IGF-1 (Fig. 7B ). age mass of 2419.7 Da; observed mass of 2419.8 Da) and ex-As shown in lane 1, two bands were detected with antihibited loss of nitrogen as a result of photoactivation by the IGFBP-2 antiserum: IGFBP-2 itself and the bedG'IGF-1IIGF-337-nm laser, to yield a second peak at 2394.3 Da. The identi-BP-2 complex. This complex bound to and was specifically ties of the CG and D fragments, containing Lys identify the site of photoincorporation of abG'IGF-1, the abG'IGF-1IIGFBP-2 complex was isolated by HPLC following complex was first reduced and alkylated with tris(2-carboxy-reduction and alkylation of the photolysis reaction mixture. ethylyl)phosphine and 4-vinylpyridine prior to electrophoresis.
Owing to the similar retention times of the free and crossAs discussed above, reduction and alkylation of bedG 1 IGF-1• linked species, the two components overlapped significantly IGFBP-2 should yield IGFBP-2 biotinylated at the site of pho- (Fig. 8A) . Subsequent re-chromatography of each component toincorporation. As shown in lanes 4-6, two bands were again provided sufficient resolution to attain a high level of purificadetected with reduction and alkylation of the samples. The tion of the abG'IGF-1-IGFBP-2 complex (Fig. 8B ). Immunoblot upper band had the same electrophoretic mobility as uncross-analysis of the column fractions indicated that >40% photoinlinked, reduced, and alkylated IGFBP-2 and was detectable corporation was achieved. with anti-IGFBP-2 antibodies. However, roughly one-half of Fractions containing purified abG'IGF-1IGFBP-2 were the content of this band was retained on the avidin-agarose pooled, dried, and trypsinized. It was anticipated that tryptic column (lane 5) and reacted with NeutrAvidin -peroxidase digestion of the abG trAvidinTM-peroxidase (Av-HRP) as indicated. Some aliquots were apabGIlIGF-1 (M) plied to an UltraLinkTM avidin-agarose (AW-Ag) column; the low pH eluate was run on the gel. RedlAlk, reduction and alkylation.
100-
valently incorporated into the C-terminal tryptic peptide of IGFBP-2 corresponding to residues 266-287 (BP2T predicted
75-
mass of 2772 Da), yielding a complex with a predicted mass of 5293 Da. To further validate this assignment, the fraction Specific containing this complex was subdigested with Staphylococcus Binding 50 aureus V8 protease and analyzed by MALDI-TOF-MS. As il-(% Maximal) -lustrated in Fig. 9 (B and C), ALDI-TOF-MS of this fraction identified four distinct peptides consistent with the proposed structure. These data indicate that when attached to the a-
25-
amino group of Gly', the azidobenzoyl moiety contacts IGFBP-2 in its distal C-terminal end within the tryptic peptide corresponding to residues 266-287 (see Fig. 11A ). o0, n Identification of the bedG'IGF-1 Photoincorporation analyzed with a polyethylene glycol precipitation-based assay using reduced and alkylated with tris(2-carboxyethylyl)phosphine IGF-1 (e), abG'IGF-1 (0), or bedG'IGF-I(D) to compete with ' 25 I-IGF-1 and 4-vinylpyridine, resulting in cleavage of IGF-1 from the for binding to IGFBP-2 (see "Experimental Procedures"). Data points complex and biotinylation of IGFBP-2 at the site of photoincorshown are average values of two independent experiments performed in poration. The mixture was then desalted on a C 4 column, dried triplicate. Binding curves were generated as described under "Experi-in vacuo, and digested with trypsin. The tryptic peptides were mental Procedures."
i auaddgse ihtysn h rpi etdswr loaded onto an UltraLinkTM monomeric avidin column, which was washed with 6 column volumes of phosphate-buffered sato a Cis column and eluted with a shallow gradient of acetoni-line. To release retained biotinylated tryptic peptides, the coltrile to obtain optimal separation of the tryptic peptides (data umn was eluted with regeneration buffer (0.2 M glycine (pH not shown). MALDI-TOF-MS was then performed on each frac-2.8)). The flow-through/washes and eluate fractions were tion to locate BP2T-abIGF1T. The MALDI mass spectrum of pooled separately and dried, and the peptides present in each the identified fraction is shown in Fig. 9A . Although not pure, were resolved by HPLC on a C 1 8 column. As expected, the we obtained a significant enrichment of BP2T-abIGF1T in this majority of peptides eluted in the flow-through fraction of the fraction with an observed mass of 5295.6 Da. These results avidin column (Fig. 10A) , resembling a representative comsuggest that abIGF1T (predicted mass of 2521 Da) was co-bined tryptic digest of uncross-linked IGF-1 and IGFBP-2 (data A 100 ported by the data presented in Fig. 7B (lanes 4-6) , where we sites in the C terminus of IGFBP-2, within tryptic peptides 0 C 10 266-287 (abG'IGF-1) and 212-227 (bedG 1 IGF-1) (Fig. 11A) . 6 20 
4'o do 8s0
The labeling of these different sites can be attributed to the Time (min) different side chain lengths of the two IGF-1 photoprobes. FIG. 8 . Purification of IGF-I1IGFBP-2 complexes. A, following abG 1 IGF-1 contains an azidobenzoyl moiety and thus lacks an reduction and alkylation, the abG'IGF-1/IGFBP-2 photolysis reaction appreciable side chain between the a-amino group of Gly 1 and mixture was purified on a C 18 column equilibrated in 0.1% trifluoroace-the aryl azide. In this case, the aryl azide resides near the outer tic acid and 24% acetonitrile. B, the major components (a-c) of the edge of the IGF-1-binding domain, defining the site of contact elution profile obtained in A were re-chromatographed separately using a shallow acetonitrile gradient. Insets, fractions from each run were for Gly'. The longer, more flexible side chain present on the analyzed by immunoblotting with anti-IGFBP-2 antibody. B, IGFBP-2; aryl azide in bedG'IGF-1 has the potential to define a contact BI, IGF-1-IGFBP-2 complex.
site within the vicinity of the other residues of the IGFBPbinding domain, including Glu, which plays an essential role not shown). Two major peaks were observed in the low pH in maintaining high affinity binding to the IGFBPs (43). Alelution of the column. The first peak exhibited a mass of 2595.7 though we cannot rule out the possibility that this side chain Da when analyzed by MALDI-TOF-MS (Fig. 10B) . When cor-results in the labeling of regions of the IGFBPs outside the rected for the mass of the biotin and remaining cross-linker IGF-binding domain, we believe that the likelihood of this residues from the bed moiety (653.3 Da), this corresponded to a occurring is minimal based on the previous identifications of BP2T fragment of 1942.3 Da (Fig. 10B ). This coincides with C-terminal binding activity described above. Given the globutryptic peptide 212-227 (predicted mass of 1942.2 Da) from the lar nature of the IGFBPs and the disulfide bonding pattern in C terminus of IGFBP-2. MALDI-TOF-MS analysis of the sec-this domain (Fig. 11B) (41) , these two sites are likely to be ond peak eluted from the avidin column revealed the presence closely apposed in three-dimensional space. Although the two of a major signal at 1667.4 Da. When corrected for cross-linker/ photoprobes labeled sites within the C terminus of IGFBP-2 biotin, the BP2T fragment had a mass of 1014.1 Da, which did that are separated by -40 amino acids in the primary senot correspond to any tryptic peptides present in rhIGFBP-2 quence, these sites are likely to be much closer when the (Fig. lOB) . However, this mass did correspond to the first 9 secondary structure of the protein is taken into consideration residues of the BP2T fragment already identified (residues (Fig. liB) . Indeed, the two labeled sites cannot be farther apart 212-220). These findings suggest that photoaffinity labeling than the total length of the two photoprobe spacer arms comwith the bed reagent resulted in partial peptide bond cleavage bined (-300 nm). at the site of covalent insertion. The potential for peptide bond Based on chemical modifications, site-directed mutagenesis cleavage during photoaffinity labeling has previously been suggested in the literature (37). This conclusion is further sup-2 M. J. Homey and S. A. Rosenzweig, manuscript in preparation. S. aureus V8 protease. Shown is the nsz mIz MALDI-TOF mass spectrum of the digestion products. C, the peptides identified in the V8 digest in B are indicated. C 0 0 0 10 . Analysis of bedG'IGF-I'IGFBP-2 photoaffinity-labeled complex. A, elution profile of the reduced, alkylated, and trypsin-digested photolysis reaction mixture following chromatography on a column of monomeric avidin. Shown are the HPLC column profiles of the column flow-through/washes and eluate. B, MALDI-TOF mass spectrum of the peaks identified by arrows in A. The first peak exhibited a mass of 2595.7 Da. After correcting the observed mass for the associated biotin and spacer, it was identified as tryptic peptide 212-227. The second biotinylated component (second arrow) was identified as having a mass of 1014.1 Da, which corresponds to a truncated form of the same tryptic peptide (residues 212-220) and suggests rupture of the peptide backbone of IGFBP-2 during photoincorporation. This finding explains the composition of the smaller band observed in Fig. 7B (loss of -7 kDa; residues 221-289). Z, pyridylethylated cysteine. IGFBP complexes (50, 51) . It is possible ing activity. More recently, Kalus et al. (46) reported that to speculate that such conformational changes may reflect the N-terminal fragments of IGFBP-5 representing residues 1-104 ability of the IGFBP, following initial binding to the N termiand 40-92 exhibit weak IGF-binding activity. Based on NMR nus (IGFBP-binding domain) of IGF-1, to interact with the studies, they defined a hydrophobic patch comprising residues IGF-1R domain of IGF-1. This could provide a steric mecha-49, 50, 62, and 68-75 that potentially represents the primary nism through which inhibition of IGF-1R activation is accom-IGF-binding site on IGFBP-5. This hypothesis was subse-plished. This in turn explains low affinity insulin binding to the quently tested by the construction of full-length IGIFBP-5 and N terminus of IGFBP-related protein-1 (9) . In addition, a con-IGFBP-3 mutants in which combined substitutions at residues formational change explains why des-1-3-IGF-1 does not bind 68, 69, 70, 73, and 74 resulted in a >1000-fold reduction in the IGFBPs well, even though it still contains an intact IGFbinding affinity (47) . Contrary to these mutagenesis results, 1R-binding domain. Stiindker et al. (48) reported that the C terminus of This scheme may serve to explain how N-terminal fragments contains the IGF-binding domain based on the isolation of a and truncation mutants of the IGFBPs are able to bind to naturally occurring, biologically active truncation of IGFBP-5. IGF-1. This would also support a steric hindrance-based model The observation by Yamanaka et al. (24) that insulin can bind of IGFBP inhibition of IGF-1 action at the IGF-1R. Following to (and be chemically cross-linked into) the N terminus of high affinity binding between the IGFBP-binding domain on IGFBP-related protein-1 may provide further insight into the IGF-1 and its contact site within the C terminus of IGFBP-2, mechanism of IGF/IGFBP interactions, suggesting the notion the ensuing conformational rearrangement enables high affinthat the N-and C-terminal domains may both interact with ity interaction of the N terminus of IGFBP-2 with the IGF-1R IGF-1, but with differing specificity and function (49) .
binding domain on IGF-1. Obviously, this is one of several In the context of the present findings, we propose the follow-potential models one might propose; confirmation of any such ing model (Fig. 12) based on the idea that two binding sites for model will require a more definitive understanding of the IGF-1 exist on the IGFBPs. The first is a high affinity, high three-dimensional structure of the IGFBPs. Future photolabel-
